These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 573408

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
    Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE.
    Cancer Res; 1988 Feb 01; 48(3):694-701. PubMed ID: 3335031
    [Abstract] [Full Text] [Related]

  • 3. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain.
    Erdlenbruch B, Schinkhof C, Kugler W, Heinemann DE, Herms J, Eibl H, Lakomek M.
    Br J Pharmacol; 2003 Jun 01; 139(4):685-94. PubMed ID: 12812991
    [Abstract] [Full Text] [Related]

  • 4. Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats.
    Pan GY, Liu XD, Liu GQ.
    Acta Pharmacol Sin; 2000 Jul 01; 21(7):613-6. PubMed ID: 11360668
    [Abstract] [Full Text] [Related]

  • 5. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
    Cosolo W, Christophidis N.
    Cancer Res; 1987 Dec 01; 47(23):6225-8. PubMed ID: 3119195
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
    Hsieh CH, Chen YF, Chen FD, Hwang JJ, Chen JC, Liu RS, Kai JJ, Chang CW, Wang HE.
    J Nucl Med; 2005 Nov 01; 46(11):1858-65. PubMed ID: 16269600
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hydroxyethyl starch solution attenuates blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.
    Chi OZ, Lu X, Wei HM, Williams JA, Weiss HR.
    Anesth Analg; 1996 Aug 01; 83(2):336-41. PubMed ID: 8694315
    [Abstract] [Full Text] [Related]

  • 10. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
    Miyagami M, Kagawa Y, Tsubokawa T.
    No Shinkei Geka; 1985 Sep 01; 13(9):955-63. PubMed ID: 2999632
    [Abstract] [Full Text] [Related]

  • 11. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.
    Kaya M, Gulturk S, Elmas I, Kalayci R, Arican N, Kocyildiz ZC, Kucuk M, Yorulmaz H, Sivas A.
    Life Sci; 2004 Nov 26; 76(2):201-12. PubMed ID: 15519365
    [Abstract] [Full Text] [Related]

  • 12. Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain.
    Bullard DE, Bourdon M, Bigner DD.
    J Neurosurg; 1984 Nov 26; 61(5):901-11. PubMed ID: 6436447
    [Abstract] [Full Text] [Related]

  • 13. The effects of pentobarbital on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.
    Chi OZ, Chun TW, Liu X, Weiss HR.
    Anesth Analg; 1998 Jun 26; 86(6):1230-5. PubMed ID: 9620510
    [Abstract] [Full Text] [Related]

  • 14. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog.
    Neuwelt EA, Frenkel EP, Rapoport S, Barnett P.
    Neurosurgery; 1980 Jul 26; 7(1):36-43. PubMed ID: 6774280
    [Abstract] [Full Text] [Related]

  • 15. Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor.
    Nakagawa H, Fujita T, Kubo S, Tokiyoshi K, Yamada M, Kanayama T, Hagiwara Y, Nakanomyo H, Hiraoka M.
    Cancer Chemother Pharmacol; 1996 Jul 26; 37(4):317-26. PubMed ID: 8548876
    [Abstract] [Full Text] [Related]

  • 16. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport SI, Barnett PA, Lewis SE, Ehle AL, Beyer CW.
    Cancer Treat Rep; 1981 Jul 26; 65 Suppl 2():39-43. PubMed ID: 6809316
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.
    Neuwelt EA, Maravilla KR, Frenkel EP, Rapaport SI, Hill SA, Barnett PA.
    J Clin Invest; 1979 Aug 26; 64(2):684-8. PubMed ID: 457877
    [Abstract] [Full Text] [Related]

  • 19. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries.
    Erdlenbruch B, Alipour M, Fricker G, Miller DS, Kugler W, Eibl H, Lakomek M.
    Br J Pharmacol; 2003 Dec 26; 140(7):1201-10. PubMed ID: 14597599
    [Abstract] [Full Text] [Related]

  • 20. Inability of dimethyl sulfoxide and 5-fluorouracil to open the blood-brain barrier.
    Neuwelt EA, Barnett P, Barranger J, McCormick C, Pagel M, Frenkel E.
    Neurosurgery; 1983 Jan 26; 12(1):29-34. PubMed ID: 6219298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.